Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Atara Biotherapeutics (ATRA) over the last 4 years, with Q1 2025 value amounting to $250000.0.

  • Atara Biotherapeutics' Gains from Investment Securities rose 1013.22% to $250000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $485000.0, marking a year-over-year increase of 14338.1%. This contributed to the annual value of $16500.0 for FY2024, which is 9121.2% down from last year.
  • Latest data reveals that Atara Biotherapeutics reported Gains from Investment Securities of $250000.0 as of Q1 2025, which was up 1013.22% from $235000.0 recorded in Q4 2024.
  • In the past 5 years, Atara Biotherapeutics' Gains from Investment Securities registered a high of $49.6 million during Q2 2022, and its lowest value of -$1.8 million during Q4 2023.
  • Over the past 4 years, Atara Biotherapeutics' median Gains from Investment Securities value was $233000.0 (recorded in 2024), while the average stood at $4.6 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' Gains from Investment Securities plummeted by 9957.28% in 2023, and later surged by 11323.94% in 2024.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Gains from Investment Securities stood at $49.6 million in 2022, then plummeted by 103.58% to -$1.8 million in 2023, then soared by 113.24% to $235000.0 in 2024, then increased by 6.38% to $250000.0 in 2025.
  • Its Gains from Investment Securities was $250000.0 in Q1 2025, compared to $235000.0 in Q4 2024 and $197000.0 in Q3 2024.